icddr,b’s research leads to approval of the fourth single-dose HPV vaccine for public use

Groundbreaking research conducted by icddr,b has played a key role in the World Health Organization’s (WHO) approval of Cecolin®, the fourth HPV vaccine, for public use in a single dose.

The approval marks significant progress in the fight against cervical cancer, which claims the life of a woman every two minutes, with 90% of these deaths occurring in low- and middle-income countries.

The CVIA 087 (CHOISES) study, led by icddr,b in collaboration with PATH and partners in Ghana from 2021 to 2023, provided the critical data needed for the approval of Cecolin®. The vaccine, produced by Innovax in China, has now been recommended by the WHO as a single-dose vaccine, providing a new option for countries facing vaccine shortages, according to a press release.

“Our study has proven the safety and efficacy of Cecolin® as a single-dose vaccine, providing a viable option for countries struggling with vaccine shortages,” said Dr. K Zaman, senior scientist at icddr,b and principal investigator of the trial.

“Bangladesh’s involvement in this global breakthrough is a moment of pride, and we hope it builds confidence in the HPV vaccination program.”

The approval of Cecolin® is expected to have a profound impact on global immunization policies, especially in countries where access to vaccines is limited. WHO Director-General Dr. Tedros Adhanom Ghebreyesus emphasized the importance of the approval, saying: “Unlike most other cancers, we have the power to eradicate cervical cancer, along with its painful inequalities. “By adding another option for a single-dose HPV vaccination schedule, we have taken another step closer to making cervical cancer a thing of the past.”

Dr. Tahmeed Ahmed, executive director of icddr,b, emphasized the importance of the HPV vaccination program in Bangladesh, where the government offers free vaccines to girls aged 10 to 14 or to girls in grades 5 to 9.

“This is a crucial opportunity to protect our daughters from cervical cancer. Vaccination is our strongest defense, and I encourage all parents and guardians to ensure their girls receive this life-saving vaccine. It is a priority not only for those who qualify for the free program but for everyone at risk.”

With over 660,000 cases of cervical cancer reported worldwide each year, and 95% of these cases caused by HPV, the need for accessible vaccines has never been more urgent. The majority of deaths occur in low- and middle-income countries, further underscoring the importance of the approval of Cecolin® as a cost-effective solution.

WHO’s announcement marks an important milestone in global health, giving more countries access to affordable and effective HPV vaccines. icddr,b’s research continues to contribute to this mission by shaping public health policy and saving lives.